文献速递前列腺癌

低危前列腺癌男性主动监测的强度及向治疗过渡的情况

Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2019-06-22

该基于人群的队列研究纳入2008-2017年瑞典斯德哥尔摩县6021例低危前列腺癌男性,其中3116例(52%)以主动监测(AS)为预期主要管理方式;随访中位3.5年,诊断后1、2、3年内至少一次PSA检测频率分别为90%、92%、88%,监测活检频率分别为42%、19%、18%;AS队列中13%在再活检时升级,Gleason升级是启动根治性治疗的最强因素;结论认为AS使用不足且监测与现行指南存在差异。

要点

  • 低危前列腺癌中仅52%以主动监测为预期主要管理方式。
  • 诊断后1、2、3年内至少一次PSA检测频率分别为90%、92%、88%。
  • 诊断后1、2、3年内监测活检频率分别为42%、19%、18%。

核心结论

  • 结果表明主动监测使用不足,且监测情况与现行指南存在差异。
  • 优化主动监测方案对于提高依从性和避免过度治疗很重要。

研究设计与样本

  • 基于人群的队列研究,纳入2008-2017年瑞典斯德哥尔摩县诊断的低危前列腺癌男性。
  • 共6021例男性纳入分析,其中3116例(52%)以主动监测为预期主要管理方式(AS队列)。
  • 随访最长10年,中位随访3.5年。
  • 采用泊松回归估计PSA检测和活检的发生率比,采用Cox回归估计开始根治性治疗的风险比。

主要发现

  • 诊断后1、2、3年内至少一次PSA检测的频率分别为90%、92%、88%。
  • 诊断后1、2、3年内监测活检的频率分别为42%、19%、18%。
  • 主动监测期间,AS队列中13%的男性在再活检时升级。
  • Gleason升级是启动根治性治疗的最强因素。

局限性

  • 一个局限性是研究结果对其他人群的普遍性受限,因为监测方案和临床环境存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Active surveillance (AS) is increasingly utilized for low-risk prostate cancers, to delay or avoid treatment. OBJECTIVE: To (1) describe uptake and surveillance intensity of real-world use of AS and compare with national guidelines, and (2) describe transitions from conservative to curative treatment by different indications of disease progression. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort study of men diagnosed with low-risk prostate cancer, in Stockholm County, Sweden, during 2008-2017. Follow-up was up to 10yr, with a median of 3.5yr. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Poisson regression was used to estimate incidence rate ratios of prostate-specific antigen (PSA) testing and biopsies. Cox regression was used to estimate hazard ratios of starting curative treatment. RESULTS AND LIMITATIONS: A total of 6021 men with low-risk prostate cancer were included in the analysis; 3116 (52%) had AS recorded as the intended primary management (AS cohort). During 1, 2, and 3yr after diagnosis, the frequencies of at least one PSA test were 90%, 92%, and 88%, respectively, and those of postdiagnostic surveillance biopsies were 42%, 19% and 18%, respectively. During surveillance, 13% of men in the AS cohort were upgraded on rebiopsy, with Gleason upgrading being the strongest factor for starting curative treatment. One limitation is the generalizability to other populations because of differences between surveillance protocols and clinical settings. CONCLUSIONS: Our results show that AS is underutilized and that monitoring differs from current guidelines. Optimization of AS protocols is important in order to increase adherence and avoid overtreatment. PATIENT SUMMARY: Active surveillance has the potential to reduce overtreatment and avoid treatment-related side effects. Our results show that few men receive the recommended monitoring.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Olsson H, Nordström T, Clements M, et al. Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. Eur Urol Oncol. 2019. PMID: 31235395. doi:10.1016/j.euo.2019.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。